You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

56 Results
Guidelines and Advice
Status: Education and Information
ID: 6-6 Version 2
Version: 2
Jan 2012
Guidelines and Advice
Status: Archived
ID: 17-8
Jan 2014
Guidelines and Advice
Status: Current
ID: GL-C50-14
Mar 2014
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
Feb 2025
 
Statistical Reports
Nov 2022
Guidelines and Advice
Status: Archived
ID: DAP
Jun 2007
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    olaparib - For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative high risk early breast cancer, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024

Pages